Zobrazeno 11 - 20
of 141
pro vyhledávání: '"Toru Sakura"'
Autor:
James Kalabus, Hitoshi Kiyoi, Yoshinobu Maeda, Yukio Kobayashi, J. Morris, Cedric Dos Santos, Toshihiro Miyamoto, Iekuni Oh, Yuqi Chen, Abraham Anderson, Yasuhiro Nakashima, Hiroatsu Iida, Tomoko Hata, Toru Sakura, Hironobu Minami, Catherine A. Tuglus
Publikováno v:
Cancer Science
Adult patients with relapsed/refractory (R/R) B‐precursor acute lymphoblastic leukemia (ALL) have a poor prognosis. Blinatumomab is a bispecific T‐cell engager (BiTE) immuno‐oncology therapy with dual specificity for CD19 and CD3 that redirects
Autor:
Heiwa Kanamori, Tohru Murayama, Yasushi Miyazaki, Yukiyasu Ozawa, Yoshiko Atsuta, Tatsuo Ichinohe, Junichi Mukae, Tadakazu Kondo, Noriko Usui, Yoshinori Tanaka, Kiyotoshi Imai, Junji Tanaka, Shuichi Ota, Fumihiko Hayakawa, Satoshi Nishiwaki, Shigeki Ohtake, Takahiro Fukuda, Shuichi Mizuta, Itaru Matsumura, Shinichi Kako, Shingo Kurahashi, Hitoshi Kiyoi, Toru Sakura
Publikováno v:
International journal of hematology. 114(5)
The optimal treatment for Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) has not been established in the high-intensity chemotherapy era. The outcomes of patients with Ph-negative ALL who un
Autor:
Toru Sakura, Shinichi Kako, Masatsugu Tanaka, Makoto Onizuka, Shingo Yano, Takehiko Mori, Rie Yamazaki, Satoshi Takahashi, Shin ichiro Fujiwara, Reiko Watanabe, Hideki Nakasone, Emiko Sakaida, Hiroaki Shimizu, Akira Yokota, Kensuke Usuki, Nobuyuki Aotsuka, Yoshihiro Hatta, Yoshinobu Kanda, Moritaka Gotoh, Takayoshi Tachibana, Shin Fujisawa, Nobuhiro Tsukada, Heiwa Kanamori, Maki Hagihara
Publikováno v:
Transplantation and cellular therapy. 27(9)
Molecular relapse after allogeneic hematopoietic cell transplantation (allo-HCT) has been thought to predict clinical relapse in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (PhALL). Tyrosine kinase inhibitor (TKI) ad
Autor:
Kensuke Usuki, Shoichi Ohwada, Taiga Takagi, Toru Sakura, Takeshi Takahashi, Hitoshi Ohno, Kosei Matsue, Sakura Sakajiri, Masato Murakami, Ryota Imanaka
Publikováno v:
International Journal of Hematology. 110:665-674
FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations in patients with acute myeloid leukemia (AML) are associated with early relapse and poor survival. This multicenter, single-arm, two-stage phase 2 study (NCT02984995) was c
Autor:
Masamitsu Yanada, Masayoshi Masuko, Yoshiko Atsuta, Tadakazu Kondo, Jun Aoki, Toru Sakura, Yuta Katayama, Junya Kanda, Tatsuo Ichinohe, Heiwa Kanamori, Masashi Sawa, Kaito Harada, Shingo Yano, Jinichi Mori, Takahiro Fukuda, Noriko Doki, Naoyuki Uchida
Publikováno v:
Annals of Hematology. 98:2179-2186
The prognosis of patients with acute myeloid leukemia (AML) is dismal after experiencing multiple relapses. This study retrospectively analyzed outcomes of allogeneic hematopoietic cell transplantation (HCT) for 192 adults with AML in third or subseq
Autor:
Kazuteru Ohashi, Tatsuo Ichinohe, Takahiro Fukuda, Tetsuya Eto, Yoshimitsu Shimomura, Takashi Ikeda, Junya Kanda, Koji Iwato, Ken Ishiyama, Takayoshi Tachibana, Yoshiko Atsuta, Toru Sakura, Takayuki Ishikawa, Masahiko Hara, Yoshinobu Kanda, Hideyuki Nakazawa
Publikováno v:
British Journal of Haematology. 186:86-90
Though second allogenic haematopoietic stem cell transplantation (HSCT) is considered a curative treatment option after myelodysplastic syndrome (MDS) relapse, scant epidemiological data are available. We investigated the outcomes and prognostic fact
Autor:
Shuichi Ota, Yoshinobu Kanda, Fumihiko Kimura, Tatsuo Ichinohe, Kota Yoshifuji, Naoyuki Uchida, Yukiyasu Ozawa, Toru Sakura, Tetsuya Eto, Junya Kanda, Takehiko Mori, Ken Ishiyama, Toshio Yabe, Takahiro Fukuda, Koji Iwato, Yoshiko Atsuta, Donor
Publikováno v:
Bone Marrow Transplantation. 54:1676-1685
The effects of ABO incompatibility on hematopoietic stem cell transplantation remain controversial. Large cohorts are required to obtain findings that allow for definite conclusions. We previously demonstrated poor overall survival and increased trea
Autor:
Kazuteru Ohashi, Yuju Ohno, Tatsuo Ichinohe, Takayuki Ishikawa, Takahiro Fukuda, Ken Ishiyama, Koji Iwato, Yoshiko Atsuta, Tadakazu Kondo, Jun Aoki, Hidehiro Itonaga, Yasushi Miyazaki, Naoyuki Uchida, Toru Sakura, Yasunori Ueda, Minoko Takanashi, Kazunari Aoki, Hirokazu Okumura
Publikováno v:
Annals of Hematology. 98:1367-1381
We conducted a nationwide retrospective study to evaluate the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in 651 patients aged 60–69 years with de novo myelodysplastic syndrome (MDS). We divided patients into two grou
Publikováno v:
International Journal of Hematology. 109:463-469
Primary graft failure (PGF) is a lethal complication that occurs early after allogeneic stem cell transplantation (allo-SCT). Cord blood transplantation (CBT) is a potential re-transplantation option. Total body irradiation (TBI) is often incorporate
Autor:
Nobuharu Kosugi, Yasuhiro Maeda, Yuichiro Nawa, Hiroyuki Kuroda, Hajime Kobayashi, Koiti Inokuchi, Chikashi Yoshida, Takashi Kumagai, Takafumi Nakao, Masato Shikami, Eisei Kondo, Kenji Imajo, Takeshi Kondo, Hiroshi Kosugi, Satoshi Morita, Sho Komukai, Atsushi Kawaguchi, Yoshinobu Maeda, Noriko Doki, Kensuke Kojima, Hiroshi Harada, Yoko Tabe, Akio Saito, Junji Nishida, Masahiro Ogasawara, Kensuke Usuki, Shin Fujisawa, Yoshinobu Kanda, Shinya Kimura, Junichi Sakamoto, Toru Sakura, Yasunori Ueda
Publikováno v:
International Journal of Clinical Oncology
Background Treatment-free remission (TFR), the ability to maintain a molecular response (MR), occurs in approximately 50% of patients with chronic myelogenous leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Methods A multicenter phase